Cortical	cortical	O	O
motor	motor	O	O
overactivation	overactivation	O	O
in	in	O	O
parkinsonian	parkinsonian	O	O
patients	patients	O	O
with	with	O	O
L-dopa-induced	l-dopa-induced	O	O
peak-dose	peak-dose	O	O
dyskinesia	dyskinesia	O	S_disease
.	.	O	O

We	we	O	O
have	have	O	O
studied	studied	O	O
the	the	O	O
regional	regional	O	O
cerebral	cerebral	O	O
blood	blood	O	O
flow	flow	O	O
(	(	O	O
rCBF	rcbf	O	O
)	)	O	O
changes	changes	O	O
induced	induced	O	O
by	by	O	O
the	the	O	O
execution	execution	O	O
of	of	O	O
a	a	O	O
finger-to-thumb	finger-to-thumb	O	O
opposition	opposition	O	O
motor	motor	O	O
task	task	O	O
in	in	O	O
the	the	O	O
supplementary	supplementary	O	O
and	and	O	O
primary	primary	O	O
motor	motor	O	O
cortex	cortex	O	O
of	of	O	O
two	two	O	O
groups	groups	O	O
of	of	O	O
parkinsonian	parkinsonian	O	O
patients	patients	O	O
on	on	O	O
L-dopa	l-dopa	S_chemicals	O
medication	medication	O	O
,	,	O	O
the	the	O	O
first	first	O	O
one	one	O	O
without	without	O	O
L-dopa	l-dopa	S_chemicals	O
induced	induced	O	O
dyskinesia	dyskinesia	O	S_disease
(	(	O	O
n	n	O	O
=	=	O	O
23	23	O	O
)	)	O	O
and	and	O	O
the	the	O	O
other	other	O	O
with	with	O	O
moderate	moderate	O	O
peak-dose	peak-dose	O	O
dyskinesia	dyskinesia	O	S_disease
(	(	O	O
n	n	O	O
=	=	O	O
15	15	O	O
)	)	O	O
,	,	O	O
and	and	O	O
of	of	O	O
a	a	O	O
group	group	O	O
of	of	O	O
14	14	O	O
normal	normal	O	O
subjects	subjects	O	O
.	.	O	O

Single	single	O	O
photon	photon	O	O
emission	emission	O	O
tomography	tomography	O	O
with	with	O	O
i.v	i.v	O	O
.	.	O	O

133Xe	133xe	O	O
was	was	O	O
used	used	O	O
to	to	O	O
measure	measure	O	O
the	the	O	O
rCBF	rcbf	O	O
changes	changes	O	O
.	.	O	O

The	the	O	O
dyskinetic	dyskinetic	O	S_disease
parkinsonian	parkinsonian	O	O
patients	patients	O	O
exhibited	exhibited	O	O
a	a	O	O
pattern	pattern	O	O
of	of	O	O
response	response	O	O
which	which	O	O
was	was	O	O
markedly	markedly	O	O
different	different	O	O
from	from	O	O
those	those	O	O
of	of	O	O
the	the	O	O
normal	normal	O	O
subjects	subjects	O	O
and	and	O	O
non-dyskinetic	non-dyskinetic	O	O
parkinsonian	parkinsonian	O	O
patients	patients	O	O
,	,	O	O
with	with	O	O
a	a	O	O
significant	significant	O	O
overactivation	overactivation	O	O
in	in	O	O
the	the	O	O
supplementary	supplementary	O	B_disease
motor	motor	O	I_disease
area	area	O	O
and	and	O	O
the	the	O	O
ipsi-	ipsi-	O	O
and	and	O	O
contralateral	contralateral	O	O
primary	primary	O	O
motor	motor	O	O
areas	areas	O	O
.	.	O	O

These	these	O	O
results	results	O	O
are	are	O	O
compatible	compatible	O	O
with	with	O	O
the	the	O	O
hypothesis	hypothesis	O	O
that	that	O	O
an	an	O	O
hyperkinetic	hyperkinetic	O	S_disease
abnormal	abnormal	O	O
involuntary	involuntary	O	B_disease
movement	movement	O	I_disease
,	,	O	O
like	like	O	O
L-dopa-induced	l-dopa-induced	O	O
peak	peak	O	O
dose	dose	O	O
dyskinesia	dyskinesia	O	S_disease
,	,	O	O
is	is	O	O
due	due	O	O
to	to	O	O
a	a	O	O
disinhibition	disinhibition	O	O
of	of	O	O
the	the	O	O
primary	primary	O	O
and	and	O	O
associated	associated	O	O
motor	motor	O	O
cortex	cortex	O	O
secondary	secondary	O	O
to	to	O	O
an	an	O	O
excessive	excessive	O	O
outflow	outflow	O	O
of	of	O	O
the	the	O	O
pallidothalamocortical	pallidothalamocortical	O	O
motor	motor	O	O
loop	loop	O	O
.	.	O	O

